G. Giannini

发表

Relative increase of T cells expressing the gamma/delta rather than the alpha/beta receptor in ataxia-telangiectasia.

R. Paganelli, M. Carbonari, M. Cherchi, 1990, The New England journal of medicine.

High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: a pilot study.

F. Mandelli, G. Avvisati, L. Palmisano, 2001, Haematologica.

Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation

F. Belardelli, M. de Béthune, S. Vella, 2003, AIDS.

Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides

E. Proietti, F. Belardelli, P. Sestili, 2001, AIDS.

A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.

D. Francisci, C. Tomino, S. Vella, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Risk factors and occurrence of rash in HIV‐positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside‐experienced patients with very low CD4 levels (<50 cells/mμL)

C. Tomino, S. Vella, R. Bucciardini, 2004, HIV medicine.

DELAYED AND DEFECTIVE ANTI-HIV IgM RESPONSE IN INFANTS

A. Casadei, M. Carbonari, I. Mezzaroma, 1987, The Lancet.

Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy.

E. Nicastri, M. Andreoni, S. Vella, 1997, AIDS research and human retroviruses.

C. Tomino, V. Fragola, M. Floridia, 2002, HIV medicine.

HIV phenotype switching during antiretroviral therapy: emergence of saquinavir‐resistant strains with less cytopathogenicity

E. Nicastri, M. Andreoni, S. Vella, 1997, AIDS.

Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.

C. Tomino, S. Vella, A. Binelli, 2000, Antiviral research.

Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity.

M. Andreoni, H. Jacobsen, I. Duncan, 1996, Antiviral research.

Quality of life outcomes of combination zidovudine–didanosine–nevirapine and zidovudine–didanosine for antiretroviral-naive advanced HIV-infected patients

A. Wu, M. Mirra, C. Tomino, 2000, AIDS.

Malignant Lymphomas High dose idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin’s lymphoma patients: a pilot study

G. Avvisati, L. Palmisano, C. Torromeo, 2001 .

A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.

M. Moroni, L. Contu, A. Lazzarin, 2000, AIDS research and human retroviruses.

Plasma viremia titration and RNA quantitation in ICD-p24 negative HIV type-1-infected patients.

C. Tomino, L. Sarmati, P. Iudicone, 1995, AIDS research and human retroviruses.

Hospitalizations and Costs of Treatment for Protease Inhibitor-Based Regimens in Patients with Very Advanced HIV-Infection (CD4 < 50/mm3)

C. Tomino, S. Vella, R. Bucciardini, 2000, HIV clinical trials.

Saquinavir delays the emergence of zidovudine resistance in HIV‐1 seropositive patients treated with combination therapy

E. Nicastri, M. Andreoni, S. Vella, 1998, Journal of medical virology.

Monozygotic twins: Identical or distinguishable for science and law?

D. De Leo, S. Turrina, E. Bortoletto, 2021, Medicine, science, and the law.

High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment.

M. Andreoni, S. Parisi, S. Vella, 1994, Journal of Acquired Immune Deficiency Syndromes.